• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Med Fact Book Apps
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Topics » General Psychiatry

General Psychiatry
General Psychiatry RSS Feed RSS

The First Antidepressant

November 1, 2006
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
The first patient to receive a modern antidepressant was Paula J. F., a Swiss woman admitted to the Munsterlingen asylum with depression.
Read More

EMSAM: A User-Friendly MAOI?

November 1, 2006
Shalom Feinberg, MD
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Shalom Feinberg, MD Associate Clinical Professor of Psychiatry, Albert Einstein College of Medicine and private practice, Queens, New York Dr. Feinberg has disclosed that he has no financial interests in any commercial companies pertaining to this educational activity.
EMSAM is here! Let us begin with a question that has been on everybody’s mind: Why is it named “EMSAM?"
Read More

The MAOI-Cheese Interaction: A Primer

November 1, 2006
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
The MAOIs were first introduced in the mid-1950s, and for the first decade of their use, nobody had an inkling that combining them with cheese (or any other high tyramine food) could be dangerous.
Read More

The Classic MAOIs: Our Capsule Summaries

November 1, 2006
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Arguably, the most confusing thing about MAOIs is keeping track of which medication is “tranylcypromine” and which is “phenelzine.” The following mnemonics work for Dr. Carlat, and perhaps they will for you.
Read More

Reflections on the Use of MAOIs

November 1, 2006
Jonathan Cole, MD
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Jonathan Cole, MD Professor of Psychiatry, Harvard Medical School, Senior Consultant, McLean Hospital Dr. Cole has disclosed that he has no consultant, speaking, or grant support relationships with any commercial companies pertaining to this educational activity. He has disclosed that he owns stock in both Pfizer and Bristol-Myers Squibb. Dr. Cole has disclosed that psychostimulants and oral selegiline have not been approved by the U.S. Food and Drug Administration for use in the treatment of depression. Please consult product labeling for the approved uses. Dr. Carlat has reviewed the content of the interview and has determined that there is no commercial bias present.
Dr. Cole, you have been involved in some of the seminal research in psychopharmacology over the years, including some of the early studies of MAOIs. One of the things that I’ve heard is that the early studies of MAOIs were not very impressive. Is that true?
Read More

Learning Objectives, The Use of MAOIs, TCPR, November 2006

November 1, 2006
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
After reading these articles, you should be able to…
Read More

Light Therapy for Depression: Does it Work?

October 1, 2006
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
How convincing is the evidence that light therapy actually works? The pace of research on bright light therapy has accelerated over the last few years, and recently, two meta-analyses of this research have been published, one in the American Journal of Psychiatry, and the other in the web-based Cochrane Library.
Read More

Blue Light: The Cutting Edge of Light Therapy

October 1, 2006
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
f you haven’t started hearing about the “benefits” of blue light therapy yet, you will soon. Blue light boosters argue that it is more effective than white light, and that it is the therapeutic ingredient of standard white light that eases seasonal depression.
Read More

Light Boxes: An Unscientific Test Drive

October 1, 2006
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Since I had never actually seen a light box in the flesh, I asked some of the larger companies to send me samples for a “review”—not for efficacy but for such qualities as convenience, asthetics, pleasantness, etc…
Read More

Seasonal Affective Disorder: Two Quick Takes

October 1, 2006
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Wellbutrin XL was approved for the prevention of Seasonal Affective Disorder (SAD), based on the results three studies in which over 1,000 patients with SAD (but who were well at study entry) were randomly assigned to either Wellbutrin XL 150 to 300 mg QD or placebo. Do insurance companies pay for light boxes? Many of them do … or at least they say they do!
Read More
Previous 1 2 … 148 149 150 151 152 153 154 155 156 … 176 177 Next
Carlat Total Access Subscriptions: Get access to every article on the website.

Complete access to every article you search on the website.

Shop for Total Access
Free Psychiatry Updates
The latest unbiased psychiatric information sent to your inbox.
Specify Your Interests
Featured Book
  • MFB7e_Print_App_Access.png

    Medication Fact Book for Psychiatric Practice, Seventh Edition (2024) - Regular Bound Book

    The updated 2024 reference guide covering the most commonly prescribed medications in psychiatry.
    READ MORE
Featured Video
  • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
    General Psychiatry

    KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

    Read More
Featured Podcast
  • shutterstock_2639254965.jpg
    General Psychiatry

    Psychopharm Secrets: Starting Meds

    Listen now
Recommended
  • Join Our Writing Team

    July 18, 2024
    WriteForUs.png
  • Insights About a Rare Transmissible Form of Alzheimer's Disease

    February 9, 2024
    shutterstock_2417738561_PeopleImages.com_Yuri A.png
  • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

    May 24, 2024
    DEA_Checkbox.png
  • Join Our Writing Team

    July 18, 2024
    WriteForUs.png
  • Insights About a Rare Transmissible Form of Alzheimer's Disease

    February 9, 2024
    shutterstock_2417738561_PeopleImages.com_Yuri A.png
  • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

    May 24, 2024
    DEA_Checkbox.png
  • Join Our Writing Team

    July 18, 2024
    WriteForUs.png
  • Insights About a Rare Transmissible Form of Alzheimer's Disease

    February 9, 2024
    shutterstock_2417738561_PeopleImages.com_Yuri A.png
  • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

    May 24, 2024
    DEA_Checkbox.png

About

  • About Us
  • CME Center
  • FAQ
  • Contact Us

Shop Online

  • Newsletters
  • Multimedia Subscriptions
  • Books
  • eBooks
  • ABPN Self-Assessment Courses

Newsletters

  • The Carlat Psychiatry Report
  • The Carlat Child Psychiatry Report
  • The Carlat Addiction Treatment Report
  • The Carlat Hospital Psychiatry Report
  • The Carlat Geriatric Psychiatry Report
  • The Carlat Psychotherapy Report

Contact

carlat@thecarlatreport.com

866-348-9279

PO Box 626, Newburyport MA 01950

Follow Us

Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

© 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.